• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 6-K/A filed by CASI Pharmaceuticals Inc.

    5/20/25 8:00:22 AM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CASI alert in real time by email
    6-K/A 1 tm2514612d4_6ka.htm FORM 6-K/A

     

     

      

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K/A

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE
    13a-16 OR 15d-16 UNDER
    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of May, 2025

     

    Commission File Number  001-41666

     

    CASI PHARMACEUTICALS, INC.

    (Translation of registrant’s name into English)

     

    1701-1702, China Central Office Tower 1

    No. 81 Jianguo Road, Chaoyang District

    Beijing, 100025

    People’s Republic of China

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  Form 20-F  x Form 40-F  ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Report on Form 6-K/A (the “Amendment”) of CASI Pharmaceuticals, Inc. (the "Company") amends the Company's reports on Form 6-K filed with the U.S. Securities and Exchange Commission on April 3, 2025 (Film No. 25807584), April 3, 2025 (Film No. 25810052), April 9, 2025, May 7, 2025, May 12, 2025, and May 14, 2025 (each an “Original Form 6-K”, and as amended the "Form 6-Ks"), solely to incorporate by reference the information contained in each Original Form 6-K, including the exhibits furnished therewith, into the Company's registration statements on Form F-3 as set forth below.

     

    Except as described above, this Amendment speaks as of the original respective filing date of each Original Form 6-K and does not amend, update or restate any information set forth in any Original Form 6-K or reflect any events that occurred subsequent to the original filing date of any Original Form 6-K.

     

    INCORPORATION BY REFERENCE

     

    The information included in the Form 6-Ks, including the exhibits furnished therewith, is hereby incorporated by reference into the Company's Registration Statements on Form F-3 (File No. 333-283998 and No. 333-281621) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this Report on Form 6-K is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      CASI Pharmaceuticals, Inc.
       
      By: /s/ Wei-Wu He
      Name: Wei-Wu He
      Title: Chairman & CEO
       
    Date: May 20, 2025    

     

     

     

     

     

     

     

    Get the next $CASI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CASI

    DatePrice TargetRatingAnalyst
    More analyst ratings